NCT06902038尚未招募不适用
Clinical Research on the Use of Immune Checkpoint Inhibitors Combined With Chidamide for the Functional Cure of AIDS
Jun Chen, MD0 个研究点目标入组 33 人开始时间: 2025年3月22日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 33
- 主要终点
- Time interval from antiretroviral therapy interruption to antiretroviral treatment restart
研究概览
简要总结
Evaluate the efficacy and safety of immune checkpoint inhibitors combined with chidamide as an "activate and kill" strategy to extend viral rebound time, reduce the HIV reservoir, and achieve functional cure.
详细描述
This project plans to conduct a prospective randomized controlled study, using immune checkpoint inhibitors combined with chidamide, while applying antiretroviral therapy interruption(ATI) to further enhance the immune killing effect of this strategy, with the aim of accelerating the clearance of the HIV reservoir and delaying the time of viral rebound, thereby achieving a functional cure for AIDS.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •People diagnosed with HIV infection;
- •Age ≥18 years old;
- •General good health, body mass index ≥18.0 to <35.0 kg/m2;
- •Able and willing to comply with the time requirements for research visits and evaluations;
- •have received ART therapy for at least 24 months, and plasma HIV-1 RNA < 50 copies /ml for two consecutive times with a time interval of at least 12 months;
- •During the screening period, the number of CD4+ T cells was ≥350 cells /μl(including boundary values);
- •Agree to adhere to contraception during the course of participating in the project and within 6 months after the end of the trial;
- •Willing to sign informed consent
排除标准
- •Have suffered from any serious acute disease within 8 weeks;
- •Subjects with a history of active autoimmune disease or autoimmune disease requiring systemic treatment;
- •Pre-treatment/exposure to any other immune checkpoint inhibitor [e.g., anti-programmed cell death protein 1(PD-1), anti-PD-L1, anti-PD-L2, anti-CTLA4, etc.].
- •The patient has received the following treatment:
- •Received other anti-latency drugs within 30 days prior to enrollment;
- •Radiotherapy or chemotherapy 30 days before screening;
- •Immunosuppressive therapy 60 days before screening;
- •Treatment with immunomodulators (e.g., interleukin, interferon), hydroxyurea, or phosphonic acid 60 days prior to screening
- •Receiving HIV vaccine or systemic cytotoxic chemotherapy 60 days before screening;
- •Previous immunoglobulin (IgG) therapy
- •Received blood transfusion or cell growth factor therapy in the 90 days prior to screening
- •Drugs such as rifampicin and rifambutin were being used at the time of screening or at the planned treatment stage;
- •Laboratory tests meet the following standards:
- •Absolute neutrophil count (ANC) < 1.50×109/L; Hemoglobin (Hb) < 105g/L(male) or < 95g/L(female); Platelet < 75×109/μL; International Normalized Ratio (INR) > 1× Upper Limit of Normal (ULN)
- •Serum alanine aminotransferase (ALT) > 1.5× upper limit of normal (ULN), serum aspartate aminotransferase (SGOT/AST) > 1.5× upper limit of normal (ULN), total bilirubin, direct bilirubin > 1.5× upper limit of normal (ULN), serum creatinine > 1.5× upper limit of normal (ULN), And the abnormality has clinical significance;
- •Five abnormalities of thyroid function with clinical significance: test items include triiodothyronine (T3), tetraiodothyronine (T4), free triiodothyronine (FT3), free tetraiodothyronine (FT4), and thyroid stimulating hormone (TSH).
- •The epinephrine test was abnormal and clinically significant;
- •Blood glucose and glycated hemoglobin were abnormal and clinically significant
- •Twelve-lead electrocardiogram was abnormal and clinically significant at the time of enrollment;
- •Interstitial changes were detected by chest CT at the time of enrollment;
- •Subjects with severe heart disease, symptomatic or asymptomatic arrhythmia;
- •Patients with co-infection such as HBV, HCV, syphilis, diabetes, and other liver diseases;
- •Subjects with a history of active or suspected malignancy or malignancy (other than basal cell skin cancer or cervical cancer in situ) within five years.
- •Subjects with a history of tuberculosis or active tuberculosis.
- •Subjects with psychiatric or substance abuse disorders known to interfere with the requirements of the experiment.
- •Subjects who received immunomodulatory or immunosuppressive therapy in the 24 weeks prior to first taking the study drug.
- •Pregnant and lactating women;
- •Mental illness or drug abuse interferes with the conduct of the test.
- •Histone deacetylase inhibitors, such as valproic acid, butyrate, phenyl butyrate, etc., but can be included after a 28-day washout period;
- •Patients with severe cardiac insufficiency [New York College of Cardiology (NYHA) Grade IV for cardiac insufficiency];
- •any arterial thromboembolism event, including myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack, occurred within 6 months prior to treatment induction; Standardized treatment of uncontrolled hypertension (systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100mmHg); Cardiomyopathy;
- •Patients had significant QT/QTC intervals during the screening period (Fridericia formula: QTcF=QT/RR0.33) prolonged (e.g., repeated measurements show a QTc interval >450 ms, or there is another risk of torsive ventricular TdP [e.g., heart failure, hypokalemia, familial long QT syndrome]) or combined use of drugs that may cause a prolonged QT/QTc interval;
- •Allergic or anti-drug antibodies to the drug or excipient used in this test are known.
- •The researchers judged that they were not suitable to participate in this experiment.
研究组 & 干预措施
Control group
Placebo Comparator
Saline 50ml q3w ×2
干预措施: Saline (NaCl 0,9 %) (placebo) (Drug)
Experimental sindilizumab and sidarbenamide
Experimental
100mg of sindilizumab, was dissolved into 50ml of normal saline q3w ×2+ sidarbenamide 10mg biw orally for 2 weeks
干预措施: PD-1 inhibitor (Drug)
Experimental sindilizumab
Experimental
100mg of sindilizumab, was dissolved in 50ml normal saline, q3w was administered ×2
干预措施: PD-1 inhibitor (Drug)
Experimental sindilizumab and sidarbenamide
Experimental
100mg of sindilizumab, was dissolved into 50ml of normal saline q3w ×2+ sidarbenamide 10mg biw orally for 2 weeks
干预措施: Sidarbenamide (Drug)
结局指标
主要结局
Time interval from antiretroviral therapy interruption to antiretroviral treatment restart
时间窗: From baseline to the date of antiretroviral treatment restart, up to 12 weeks
次要结局
- Changes in HIV-specific CD8+ T response from baseline with Day8 and Day29 and ART restart(From baseline to Day 8, Day 29 and antiretroviral treatment restart, up to 12 weeks)
- The ratio of HIV RNA<50 copies /ml was maintained at 12 weeks(12 weeks)
- Changes in HIV DNA levels from baseline to antiretroviral treatment restart(From baseline to the date of antiretroviral treatment restart, up to 12 weeks)
- Incidence of drug-related adverse events before antiretroviral treatment restart(From date of randomization to the date of antiretroviral treatment restart, up to 14 weeks.)
- Changes in PD-1 (+) CD4 T cells and CD8 T cells from baseline at Day8 and Day29 and ART restart(From baseline to Day 8, Day 29 and antiretroviral treatment restart, up to 12 weeks)
研究者
Jun Chen, MD
Deputy Director of Infection and Immunization
Shanghai Public Health Clinical Center
相似试验
招募中
不适用
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung CancerNon Small Cell Lung CancerNCT05059951Hunan Province Tumor Hospital15,000
Unknown
2 期
Tislelizumab and Radiotherapy for Recurrent Cervical CancerObjective Response RateRecurrent Cervical CarcinomaRadiotherapyImmune Checkpoint InhibitorsAnti-programmed Cell Death Receptor 1Survival OutcomesMetastatic Cervical CarcinomaPersistent Cervical CarcinomaImmunotherapyTislelizumabNCT05310383Lei Li58
招募中
2 期
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct CarcinomaCollecting Duct CarcinomaNCT06211114Peking University Cancer Hospital & Institute30
终止
2 期
Immunotherapy Study for Patients With Stage IV MelanomaStage IV MelanomaMetastatic MelanomaNCT02054520NewLink Genetics Corporation47
已完成
不适用
Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological TypeUncommon Pathological Types of Lung CancerNCT05023837Hunan Province Tumor Hospital40